Last Updated on September 7, 2021 by Valinda Riggins Nwadike, MD, MPH
One of the most common questions we receive is about herpes transmission and the risk of spreading the virus to a new partner.
HSV1 & HSV2 is transmitted via skin-to-skin contact – not bodily fluids, blood, surfaces, towels, bedding, toilets, or otherwise, just skin-to-skin contact. From there, inoculation must also occur for the infection to spread, and this happens via a point of entry into the system. Coming in contact with the virus on your arm, for example, won’t necessarily lead to infection, unless your arm also has a small cut, abrasion, sore, or tear providing entry for the virus into the human body – inoculation.
The Mucous Membranes
This is where the mucosa (mucous membranes) comes into play. The mucous membranes, highly porous tissues involving absorption and secretion, line cavities of the body exposed to the environment. They are continuous with the skin and reside in the nostrils, the mouth, the lips, the eyelids, the ears, the vulva, the vagina, the urethra, and the anus.
These membranes are designed to trap unwanted and harmful pathogens with mucous. At which point, the immune system is sent to kill the otherwise invasive infections trapped in the mucosa. However, the immune system is not able to combat all pathogens.
In the case of sexually transmitted infections and diseases, HSV included, the mucous membranes trap the pathogen, providing an entry point to the body, the immune system is unable to effectively combat the infection, and the pathogen enters the system.
STI Masterclass: Breaking Through the Fear, Shame, and Stigma of an STI Diagnosis
If you’re fed up with feeling unworthy, less-than, damaged, or limited by your STI, then join the next cohort in the 60-Day Masterclass, and leave feeling empowered, knowledgable, and confident again!
Click Here to Learn More
Asymptomatic Shedding
Once infected with HSV1 or HSV2, a person is capable of transmitting the virus forever, even when there are no symptoms present.
Transmission that occurs when there are no visible symptoms is a result of asymptomatic viral shedding.
Viral shedding means the virus is active on the skin. HSV can shed before an active outbreak (the prodromal period), during an outbreak, during the healing process following an outbreak, and also at random when there are no noticeable symptoms, and that is called asymptomatic viral shedding, or simply, asymptomatic shedding.
- In general, people with HSV1 asymptomatically shed the virus about 5%-10% of the time.
- In general, people with HSV2 asymptomatically shed the virus about 10%-20% of the time.
Over time, though, the percentage someone sheds the virus asymptomatically is said to decrease.
Is one type of herpes more easily spread than another?
No, not really.
Both HSV1 and HSV2 can be easily transmitted via skin-to-skin contact. HSV1 tends to prefer locations above the waist, such as the mouth, and HSV2 tends to prefer locations below the waist, such as the genitals, but both can also be easily spread to other parts of the body.
Both types are most contagious during active outbreaks – when visual symptoms are present – but they are also commonly spread when there are no recognizable symptoms through asymptomatic shedding.
Prevalence of Oral HSV1 – Cold Sores
In theory, oral HSV1 is the most easily acquired infection, because it is usually the first herpes simplex type someone encounters, and it is commonly spread by social kissing among relatives and friends. Children who have no prior infections with an HSV type do not have an acquired immune response and are most susceptible.
50% of Americans, by their teenage and young adult years, will have acquired HSV1 and will have the HSV1 antibodies, and by the time they reach age 50, 80-90% of Americans will have acquired HSV1.
In contrast, almost all HSV2 infections are encountered during teenage and adult years, once someone has become sexually active.
Is penis-to-vulva or vulva-to-penis riskier?
In general, someone with a vulva is more likely to contract an HSV infection than someone with a penis, because the majority of the vulva and vagina is comprised of mucous membranes. And while there are mucous membranes on the penis (the head of the penis, the foreskin, and the urethra), there is less exposed surface area on the penis that is made of mucous membranes than compared to the vulva and vagina.
That is why HSV transmission is actually most dependent upon the location of the body in contact with the virus rather than the gender of the person in question, because of exposure to mucous membranes themselves.
The greatest risk of transmission occurs anywhere there is contact by an infected area with a mucosa: the nostrils, the mouth, the lips, the eyelids, the ears, the anus, the vulva, the vagina, the glans penis (head of the penis), the glans clitoris, the urethra, the inside of the prepuce (foreskin), and the clitoral hood.
Percentage of HSV Risk
Let’s say you have a person with a penis who has HSV and person with a vulva who does not:
- If they avoid sexual activity during outbreaks, don’t use condoms regularly, and the person with a penis doesn’t take an antiviral therapy every day, the risk of transmission is about 10% per year, though there is a large range — from 7 percent to 31 percent — in different studies.
Let’s say you have a person with a vulva who has HSV and a person with a penis who does not:
- If they avoid sexual activity during outbreaks, don’t use condoms regularly, and the person with the vulva doesn’t take an antiviral therapy every day, the risk of transmission is about 5% per year.
Those percentages represent what studies consider an “average” sex life incorporating vaginal penetration over the course of one year’s duration, which, of course, is highly subjective.
Unfortunately, there is no available data yet on the rate of transmission between same-sex partners.
- All about Herpes Disclosure
- How to Not Give an Eff about Having an STI
- Herpes Transmission Risk – Part II
- HSV1 vs. HSV2
- STD? What Now?
- Want to share your story?
- More Information about Herpes
- HSV2 Resources and Info
- Dealing with STD Stigma
References
- Symptoms
- Armangue, Thaís, et al. “Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis.” The Lancet Neurology 17.9 (2018): 760-772.
- Groves, Mary Jo. “Genital herpes: a review.” Am Fam Physician 93.11 (2016): 928-934.
- Jonker, Iris, et al. “The association between herpes virus infections and functional somatic symptoms in a general population of adolescents. The TRAILS study.” PloS one 12.10 (2017): e0185608.
- Verhoeven, Dirk HJ, et al. “Reactivation of human herpes virus-6 after pediatric stem cell transplantation: risk factors, onset, clinical symptoms and association with severity of acute graft-versus-host disease.” The Pediatric infectious disease journal 34.10 (2015): 1118-1127.
- Croll, Benjamin J., et al. “MRI diagnosis of herpes simplex encephalitis in an elderly man with nonspecific symptoms.” Radiology case reports 12.1 (2017): 159-160.
- Testing
- Tan, S. K., and B. A. Pinsky. “Molecular Testing for Herpes Viruses.” Diagnostic Molecular Pathology. Academic Press, 2017. 89-101.
- Piret, Jocelyne, Nathalie Goyette, and Guy Boivin. “Novel method based on real-time cell analysis for drug susceptibility testing of herpes simplex virus and human cytomegalovirus.” Journal of clinical microbiology 54.8 (2016): 2120-2127.
- Hauser, Ronald G., et al. “Reply to Galen,“Screening cerebrospinal fluid prior to herpes simplex virus pcr testing might miss cases of herpes simplex encephalitis”.” Journal of clinical microbiology 55.10 (2017): 3144.
- Hauser, Ronald G., et al. “Cost-effectiveness study of criteria for screening cerebrospinal fluid to determine the need for herpes simplex virus PCR testing.” Journal of clinical microbiology 55.5 (2017): 1566-1575.
- Bohn-Wippert, Kathrin, et al. “Resistance testing of clinical herpes simplex virus type 2 isolates collected over 4 decades.” International Journal of Medical Microbiology 305.7 (2015): 644-651.
- Treatment
- Wilhelmus, Kirk R. “Antiviral treatment and other therapeutic interventions for herpes simplex virus epithelial keratitis.” Cochrane Database of Systematic Reviews 1 (2015).
- James, Scott H., and David W. Kimberlin. “Neonatal herpes simplex virus infection: epidemiology and treatment.” Clinics in perinatology 42.1 (2015): 47-59.
- Jeon, Young Hoon. “Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment.” The Korean journal of pain 28.3 (2015): 177.
- Eppink ST, Kumar S, Miele K, Chesson H. Lifetime medical costs of genital herpes in the United States: Estimates from insurance claims. Sex Transm Dis. (2021).
- Breier, Alan, et al. “Herpes simplex virus 1 infection and valacyclovir treatment in schizophrenia: Results from the VISTA study.” Schizophrenia research (2018).
- Varanasi, Siva Karthik, et al. “Azacytidine treatment inhibits the progression of herpes stromal keratitis by enhancing regulatory T cell function.” Journal of virology 91.7 (2017): e02367-16.
- Prevention
- Abdool Karim, Salim S., et al. “Tenofovir gel for the prevention of herpes simplex virus type 2 infection.” New England Journal of Medicine 373.6 (2015): 530-539.
- Jeon, Young Hoon. “Herpes zoster and postherpetic neuralgia: practical consideration for prevention and treatment.” The Korean journal of pain 28.3 (2015): 177.
- Marrazzo, Jeanne M., et al. “Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.” The Journal of infectious diseases (2019).
- Chi, Ching‐Chi, et al. “Interventions for prevention of herpes simplex labialis (cold sores on the lips).” Cochrane Database of Systematic Reviews 8 (2015).
- Colombel, Jean-Frédéric. “Herpes zoster in patients receiving JAK inhibitors for ulcerative colitis: mechanism, epidemiology, management, and prevention.” Inflammatory bowel diseases 24.10 (2018): 2173-2182.
- Transmission
- Oevermann, Lena, et al. “Transmission of chromosomally integrated human herpes virus-6A via haploidentical stem cell transplantation poses a risk for virus reactivation and associated complications.” Bone marrow transplantation (2019): 1.
- Tronstein E, Johnston C, Huang ML, Selke S, Magaret A, Warren T, Corey L, Wald A. Genital shedding of herpes simplex virus among symptomatic and asymptomatic persons with HSV-2 infection. JAMA. (2011).
- Pandey, Utsav, et al. “Inferred father-to-son transmission of herpes simplex virus results in near-perfect preservation of viral genome identity and in vivo phenotypes.” Scientific reports 7.1 (2017): 13666.
- Ramchandani M, Selke S, Magaret A, Barnum G, Huang MW, Corey L, Wald A. Prospective cohort study showing persistent HSV-2 shedding in women with genital herpes 2 years after acquisition. Sex Transm Infect. (2018).
- Ceña-Diez, Rafael, et al. “Prevention of vaginal and rectal herpes simplex virus type 2 transmission in mice: Mechanism of antiviral action.” International journal of nanomedicine 11 (2016): 2147.
- Omori, Ryosuke, and Laith J. Abu-Raddad. “Sexual network drivers of HIV and herpes simplex virus type 2 transmission.” AIDS (London, England) 31.12 (2017): 1721.
- Aebi-Popp, Karoline, et al. “High prevalence of herpes simplex virus (HSV)-type 2 co-infection among HIV-positive women in Ukraine, but no increased HIV mother-to-child transmission risk.” BMC pregnancy and childbirth 16.1 (2016): 94.
Anonymous
Thank you SO much for writing this article! As a person with genital HSV2, I always wonder what to tell my future partners regarding how high the risk of transmission is. It’s nice to actually get some statistics to share with them to help ease their mind. It’s also nice to know that I don’t asymptomatically shed as often as I thought!
Jenelle Marie
Hi Anonymous –
So happy to read that this was helpful. Stay tuned, part II and part III of this series is getting posted later today.
Thanks so much for your comments!